# LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

> **NCT01345669** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 617 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Placebo
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT01345669
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-17
- **Primary completion:** 2016-09-12
- **Final completion:** 2016-09-12
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345669, "LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01345669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*